Credits Available: 4.25 AMA PRA Category 1 Credit™/ MOC Points

Description: This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Reem Karmali

Northwestern University, Feinberg School of Medicine

Dr. Karmali’s overarching goal is to improve outcomes for patients with lymphoma though practice and research. Her clinical research focuses on identifying novel targets for drug design and development including cellular therapies. Her translational research explores on the role of metabolic dysregulation in lymphomagenesis and resistance to therapy. She has published widely, authoring more than 100 peer-reviewed journal articles.